Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Tang, Li Chen ^a   Wang, Bi Yun ^a,b   Sun, Si ^a,b   Zhang, Jian ^a,b   Jia, Zhen ^a,b   Lu, Yun Hua ^a,b   Di, Geng Hong ^a   Shao, Zhi Ming ^a   Hu, Xi Chun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Albumin bound paclitaxel; Cisplatin; Phase II study; Rash

Indexed keywords

ALBUMIN; ANTIHISTAMINIC AGENT; CISPLATIN; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARM RASH; ARTICLE; BREAST CANCER; CANCER PATIENT; CHINESE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; ERYTHRODERMA; FACE DEFORMITY; FACE RASH; FEMALE; HAND RASH; HUMAN; INCIDENCE; LEG RASH; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NECK RASH; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRURITUS; RACE DIFFERENCE; SKIN DISEASE; SKIN TOXICITY; TRUNK RASH; WESTERN HEMISPHERE; BONE NEOPLASMS; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; CLINICAL TRIAL; FOLLOW UP; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RASH; SECONDARY;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CISPLATIN; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS;

EID: 84877132818     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-232     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10(Suppl 3):20-29.
3. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007, 21(2):257-272. 10.1016/j.hoc.2007.03.001, 17512448.
4. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005, 23(25):6019-6026. 10.1200/JCO.2005.11.013, 16135470.
5. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31):7794-7803. 10.1200/JCO.2005.04.937, 16172456.
6. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 27(22):3611-3619. 10.1200/JCO.2008.18.5397, 19470941.
7. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26(10):1642-1649. 10.1200/JCO.2007.11.6699, 18375893.
8. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004, 30(1):53-81. 10.1016/S0305-7372(03)00139-7, 14766126.
9. Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001, 2(3):190-208. discussion 209, 10.3816/CBC.2001.n.022, 11899413.
10. Guan Z, Feng F, Jiang Z, Shen Z, Yu S, Fen J, Huang J, Yao Z, Bhar P. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer. Asia-Pacific J Clin Oncol 2009, (5):165-174.
11. Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011, 4:123-136. 3143911, 21792318.
12. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995, 13(10):2575-2581.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
14. Common Terminology Criteria for Adverse Events http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, Common Terminology Criteria for Adverse Events.
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100(2):229-235. 10.1007/s10549-006-9242-8, 16932852.
16. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999, 59(7):1454-1457.
17. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009, 31(8):1619-1640. 10.1016/j.clinthera.2009.08.005, 19808124.
18. ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) http://www.rxlist.com/abraxane-drug.htm.
19. Vishnu P, Roy V. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond Engl) 2010, 6(4):495-506.
20. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res 1997, 17(Suppl 1):S29-S33.
21. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997, 17(Suppl 1):S15-S21.
22. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993, 10(4):307-377.
23. Plasbumin-25 Instruction http://www.talecris-pi.info/inserts/Plasbumin25.pdf, Plasbumin-25 Instruction.
24. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005, 20(Suppl 6):vi3-vi9.
25. Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, Dees EC. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol 2008, 3(5):521-526. 10.1097/JTO.0b013e31816de2a7, 2860395, 18449006.